According to an announcement from the China Securities Regulatory Commission on March 18, Sukun Technology, a leading medical AI company, has received official approval from the China Securities Regulatory Commission on its H-share listing application. The approval is valid for 12 months from the date of approval.

Industry insiders said that the relevant approval from the Securities Regulatory Commission is commonly known as the “Great Road Rule”. The approval received by Sukun Technology means that the domestic approval process for the listing of its company's H shares has been successfully completed.

According to information, Shikun Technology submitted its prospectus in Hong Kong on September 21, 2021. Currently, it has just expired for 6 months, and the prospectus has expired. However, according to the regulations of the Hong Kong Stock Exchange, companies only need to promptly submit the new version and update the relevant data after the initial failure to continue the review process and wait for the appropriate market window to continue to impact the listing.

Founded in 2017, Sukun Technology is a global leader in medical AI solutions for disease screening, diagnosis, and treatment options and planning. Sukun Technology's digital doctor product portfolio includes 12 products and 25 candidate products, covering five key treatment areas, including the heart, brain, abdomen, chest and musculoskeletal system. It has obtained 2 National Drug Administration Class III medical device registration certificates, 11 China Drug Administration Class II medical device registration certificates, and 4 MDR CE certifications. According to third party insight reports, based on the number of registration certificates obtained, Sukun Technology ranked first in the world in this industry.